Consequences of COVID-19 for cancer care - a CRUK perspective
- PMID: 33097915
- PMCID: PMC7582444
- DOI: 10.1038/s41571-020-00446-0
Consequences of COVID-19 for cancer care - a CRUK perspective
Abstract
We reflect on the past 10 months of clinical activity in oncology in the UK during the COVID-19 pandemic and suggest how services can be protected during subsequent waves of infection.
Conflict of interest statement
C.S. receives grant support from Archer Dx, AstraZeneca, Boehringer–Ingelheim and Ono Pharmaceutical; has consulted for AstraZeneca, Bicycle Therapeutics, Celgene, Genentech, GRAIL, GSK, Illumina, Medicxi, MSD, Novartis and the Sarah Cannon Research Institute; receives grant support and has consulted for Bristol Myers Squibb, Pfizer and Roche–Ventana; is an advisory board member and is involved in trials sponsored by AstraZeneca; has stock options in Apogen Biotech-nologies, Epic Bioscience, GRAIL; and has stock options and is a co-founder of Achilles Therapeutics. E.G. declares no competing interests.
References
-
- Hiom, S. How coronavirus is impacting cancer services in the UK. Cancerresearchuk.org. https://scienceblog.cancerresearchuk.org/2020/04/21/how-coronavirus-is-i... (2020).
-
- Serle, J. Widespread service suspensions will have ‘lasting impact’. HSJ.co.uk. https://www.hsj.co.uk/coronavirus/widespread-service-suspensions-will-ha... (2020).
-
- NHS Digital. Appointments in general practice August 2020. digital.nhs.uk. https://digital.nhs.uk/data-and-information/publications/statistical/app... (2020).
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
